Use of Eltrombopag in Patients with Platelet Engraftment Failure Following Second Allogeneic Peripheral Stem Cell Transplantation
Use of Eltrombopag in Patients with Platelet Engraftment Failure Following Second Allogeneic Peripheral Stem Cell Transplantation
Thrombocytopenia after peripheral stem cell transplantation (PSCT) is associated with morbidity and mortality. Eltrombopag, athrombopoietin receptor agonist, is successfully used primarily in the treatment of chronic idiopathic thrombocytopenic purpuraand other thrombocytopenias associated with aplastic anemia and myelodysplastic syndrome. Recently, the use of eltrombopagin the treatment of thrombocytopenia after allogeneic PSCT has shown promising results. The use of eltrombopag in three patientswith hematologic malignancy who experienced graft failure after the first PSCT and developed platelet engraftment failurefollowing the second bone marrow (BM) transplantation was presented retrospectively. The patients included two males and onefemale, with the mean age of 52 (45–57) years. The diagnoses were acute myeloid leukemia, non-hodgkin lymphoma (NHL), acutelymphocytic leukemia. All patients underwent allogeneic PSCT with the myeloablative regimen. Platelet engraftment failure wasdetected during the follow-up of the patients. Acute grade 3 skin graft versus host disease developed in the patient with NHL. Mycophenolate-mofetil,cyclosporin-A, steroid-based immunosuppression therapy was given. Graft versus host disease completelyresponded to this treatment in the first week of treatment. However, thrombocytopenia persisted. None of the patients had anyviral infection or relapse. BM biopsies of patients were hypocellular, and the number of megakaryocytes were found to be decreased.Eltrombopag was initiated in three patients after 110 (60–144) days of transplantation. Responses were obtained in all ofthe patients; the platelet value was ≥30 × 103/µL (30.000–247.000). The mean duration of response was 27 (20–35) days. Althoughengraftment failure is not a routine indication of the eltrombopag, it can be used safely and effectively in patients with plateletengraftment failure after PSCT.
___
- Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso
G, et al. Factors influencing haematological recovery after allogeneic
haemopoietic stem cell transplants: graft-versus-host disease,
donor type, cytomegalovirus infections and cell dose. Br J Haematol
2001; 112: 219-27. [CrossRef]
- Nash RA, Gooley T, Davis C, Appelbaum FR. The problem of thrombocytopenia
after hematopoietic stem cell transplantation. Oncologist
1996; 1: 371-80. [CrossRef]
- Dierickx D, Delannoy A, Saja K, Verhoef G, Provan D. Anti-CD20
monoclonal antibodies and their use in adult autoimmune hematological
disorders. Ann J Hematol 2011; 86: 278-91. [CrossRef]
- Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al.
Eltrombopag for management of chronic immune thrombocytopenia
(RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;
377: 393-402. [CrossRef]
- Beck JC, Burke MJ, Tolar J. Response of refractory immune thrombocytopenia
after bone marrow transplantation to romiplostim. Pediatr
Blood Cancer 2010; 54: 490-1. [CrossRef]
- Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO. Romiplostim for
delayed platelet recovery and secondary thrombocytopenia following
allogeneic stem cell transplantation. Am J Blood Res 2013; 3: 260-4.
- Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, et al.
Eltrombopag for treatment of thrombocytopenia after allogeneic
hematopoietic cell transplantation. Biology of Blood and Marrow
Transplantation 2016; 22: 919-24. [CrossRef]
- Reid R, Bennett JM, Becker M, Chen Y, Milner L, Phillips GL 2nd, et
al. Use of eltrombopag, a thrombopoietin receptor agonist, in
post-transplantation thrombocytopenia. Am J Hematol 2012; 87:
743-5. [CrossRef]
- Kuzmina Z, Eder S, Böhm A, Pernicka E, Vormittag L, Kalhs P, et al.
Significantly worse survival of patients with NIH-defined chronic
graft-versus-host disease and thrombocytopenia or progressive onset
type: Results of a prospective study. Leukemia 2012; 26: 746-56.
[CrossRef]
- Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L, et
al. Prognostic importance of platelet count 100 days post allogeneic
bone marrow transplant. Bone Marrow Transplant 2004; 33: 419-23.
[CrossRef]
- Fujimi A, Kamihara Y, Hashimoto A, Kanisawa Y, Nakajima C, Hayasaka
N, et al. Identification of anti-thrombopoietin receptor antibody
in prolonged thrombocytopenia after allogeneic hematopoietic
stem cell transplantation treated successfully with eltrombopag. Int
J Hematol 2015; 102: 471-6. [CrossRef]
- Bielski M, Yomtovian R, Lazarus HM, Rosenthal N. Prolonged isolated
thrombocytopenia after hematopoietic stem cell transplantation:
morphologic correlation. Bone Marrow Transplant 1998; 22: 1071-6.
[CrossRef]
- First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM.
Isolated thrombocytopenia after allogeneic bone marrow transplantation:
existence of transient and chronic thrombocytopenic
syndromes. Blood 1985; 65: 368-74.
- Yamazaki R, Kuwana M, Mori T, Okazaki Y, Kawakami Y, Ikeda Y, et al.
Prolonged thrombocytopenia after allogeneic hematopoietic stem
cell transplantation: associations with impaired platelet production
and increased platelet turnover. Bone Marrow Transplant 2006; 38:
377-84. [CrossRef]
- Zhang X, Fu H, Xu L, Liu D, Wang J, Liu K, et al. Prolonged thrombocytopenia
following allogeneic hematopoietic stem cell transplantation
and its association with a reduction in ploidy and an immaturation
of megakaryocytes. Biol Blood Marrow Transplant 2011; 17:
274-80. [CrossRef]
- Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, et
al. Safety and Efficacy of Eltrombopag in Post-hematopoietic Stem
Cell Transplantation (HSCT) Thrombocytopenia. Indian J Hematol
Blood Transfus 2015; 31: 413-5. [CrossRef]